会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 10. 发明授权
    • Helicobacter pylori-colonized mongolian gerbils, method for preparation
thereof, and method for screening anti-Helicobacter pylori substance
using them
    • 幽门螺杆菌定殖的蒙古沙鼠,其制备方法,幽门螺杆菌分离培养基及使用它们的抗幽门螺杆菌物质筛选方法
    • US5929299A
    • 1999-07-27
    • US693100
    • 1996-08-09
    • Yoshifumi IkedaFumihiro HirayamaShiro Takagi
    • Yoshifumi IkedaFumihiro HirayamaShiro Takagi
    • A01K67/027A61K49/00C12Q1/04C12N5/00C12N1/00C12N15/00
    • C12R1/01A01K67/027A61K49/0008C12Q1/04G01N2333/205
    • Helicobacter pylori-colonized Mongolian gerbils prepared by oral inoculation of a broth culture obtained from a liquid culture of Helicobacter pylori, to the Mongolian gerbils for intragastric colonization of Helicobacter pylori. These Mongolian gerbil models are useful for screening the therapeutic efficacies of drugs against Helicobacter pylori, as well as elucidation of pathology of Helicobacter pylori disease in humans. Moreover, the medium of the present invention for isolating Helicobacter pylori, which is supplemented with vancomycin, trimethoprim, amphotericin B, polymyxin B and 2,3,5-triphenyltetrazolium chloride, enables selective and efficient detection of Helicobacter pylori colonized in their Mongolian gerbils which have microorganisms living in stomach. A combined use of the above-mentioned Mongolian gerbil models and the medium for isolating Helicobacter pylori enables screening of an anti-Helicobacter pylori substance at an animal levels thereby enabling accurate prediction of clinical effects of the anti-Helicobacter pylori substance.
    • PCT No.PCT / JP95 / 02531 Sec。 371日期:1996年8月9日 102(e)日期1996年8月9日PCT提交1995年12月8日PCT公布。 第WO96 / 18291号公报 日期1996年6月20日幽门螺杆菌定殖的蒙古沙鼠通过口服接种从幽门螺杆菌液体培养物获得的肉汤培养物制备成蒙古沙鼠用于幽门螺杆菌胃内定殖。 这些蒙古沙鼠模型可用于筛选药物对幽门螺杆菌的治疗功效,以及阐明人幽门螺杆菌病的病理学。 此外,本发明的用于分离补充有万古霉素,甲氧苄氨嘧啶,两性霉素B,多粘菌素B和2,3,5-三苯基四氮唑氯化物的幽门螺杆菌的培养基能够选择性和有效地检测在其蒙古沙鼠中定居的幽门螺杆菌, 有微生物住在胃里。 综合使用上述的蒙古沙鼠模型和用于分离幽门螺杆菌的培养基使得能够以动物水平筛选抗幽门螺杆菌物质,从而能够准确预测抗幽门螺杆菌物质的临床效果。